RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies	Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm	Recruiting	Phase 1	2024-12-13		NCT06732492

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nanjing Bioheng Biotech Co., Ltd.	10
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Union Hospital	Wuhan	China	1

Clinical trials